Free tool
FAERS Monitor: Rebif
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103780 or its brand name (Rebif, Interferon Beta-1a). Reports on generic versions are filed under their own applications.
Reports
47,980
Serious
36,921
77% of reports
Hospitalization
17,271
Death reported
2,806
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- multiple sclerosis relapse4,095
- fatigue2,997
- injection site erythema2,959
- influenza like illness2,933
- fall2,554
- headache2,455
- injection site pain2,431
- pain1,939
- depression1,846
- multiple sclerosis1,784
- gait disturbance1,767
- hypoaesthesia1,654
- urinary tract infection1,579
- asthenia1,577
- nausea1,451
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 314 |
| 2005 | 1,651 |
| 2006 | 571 |
| 2007 | 1,652 |
| 2008 | 2,032 |
| 2009 | 2,506 |
| 2010 | 3,611 |
| 2011 | 4,468 |
| 2012 | 4,809 |
| 2013 | 5,832 |
| 2014 | 3,083 |
| 2015 | 1,901 |
| 2016 | 1,806 |
| 2017 | 1,965 |
| 2018 | 1,969 |
| 2019 | 1,970 |
| 2020 | 1,537 |
| 2021 | 1,814 |
| 2022 | 1,632 |
| 2023 | 1,055 |
| 2024 | 790 |
| 2025 | 637 |
| 2026 | 375 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,006,179 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple sclerosis relapseSignal | 4,095 | 27.8 | 27.0 | 99,749 |
| multiple sclerosisSignal | 1,784 | 16.9 | 16.2 | 25,821 |
| influenza like illnessSignal | 2,933 | 16.2 | 15.6 | 40,377 |
| injection site erythemaSignal | 2,959 | 10.7 | 10.3 | 25,505 |
| hypoaesthesiaSignal | 1,654 | 4.9 | 4.7 | 5,089 |
| urinary tract infectionSignal | 1,579 | 4.1 | 3.9 | 3,674 |
| gait disturbanceSignal | 1,767 | 4.1 | 3.9 | 4,097 |
| depressionSignal | 1,846 | 3.6 | 3.4 | 3,435 |
| injection site painSignal | 2,431 | 3.5 | 3.4 | 4,354 |
| fallSignal | 2,554 | 3.4 | 3.3 | 4,318 |
| asthenia | 1,577 | 1.8 | 1.8 | 615 |
| headache | 2,455 | 1.7 | 1.7 | 758 |
| fatigue | 2,997 | 1.7 | 1.6 | 873 |
| pain | 1,939 | 1.4 | 1.3 | 213 |
| nausea | 1,451 | 0.8 | 0.8 | 72 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.